Cyclopentolate HCl 1% - Tropicamide 1% - PHENYLephrine HCl 2.5% in Sterile Water for Injection (O...
FDA Drug Recall #D-0013-2017 — Class II — September 20, 2016
Recall Summary
| Recall Number | D-0013-2017 |
| Classification | Class II — Moderate risk |
| Date Initiated | September 20, 2016 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Leiter's Compounding |
| Location | San Jose, CA |
| Product Type | Drugs |
| Quantity | 76,315 total units, all products |
Product Description
Cyclopentolate HCl 1% - Tropicamide 1% - PHENYLephrine HCl 2.5% in Sterile Water for Injection (Ophthalmic Solution), in a) 1 mL Total Volume (NDC 70360-017-38) and b) 10 mL Total Volume (NDC 70360-017-39) in a 15 mL Dropper Bottle, Compounded by Leiter's Compounding, San Jose, CA --- NDC 70360-017-38
Reason for Recall
Lack of Assurance of Sterility; all compounded products within expiry produced using recalled filters
Distribution Pattern
Nationwide
Lot / Code Information
All unexpired lots; a) Expirations dates of 10/03/2016 to 11/06/2016 and b) 09/25/2016 to 10/01/2016
Other Recalls from Leiter's Compounding
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0017-2017 | Class II | Placebo for Prednisolone Acetate 1%, Oph Suspen... | Sep 20, 2016 |
| D-0010-2017 | Class II | Atropine Sulfate 0.01% in 0.9% Sodium Chloride ... | Sep 20, 2016 |
| D-0011-2017 | Class II | Brilliant Blue G 0.025% in 0.9% Sodium Chloride... | Sep 20, 2016 |
| D-0016-2017 | Class II | Moxifloxacin 1 mg/mL in Sterile Balanced Salt S... | Sep 20, 2016 |
| D-0012-2017 | Class II | Cefuroxime Sodium 10 mg/mL in 0.9% Sodium Chlor... | Sep 20, 2016 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.